Transmission of hepatitis C virus by blood transfusions and other medical procedures: A global review

Prati, Daniele

doi:10.1016/j.jhep.2006.07.003

Cited by 220 publications

(184 citation statements)

References 105 publications

Supporting

Mentioning

171

Contrasting

Unclassified

Order By: Relevance

“…(10,11) In Europe and Japan, HCV is identified as one of the most common causes of chronic liver disease, and its prevalence in the population aged 61-70 years has been up to 12%. (12)(13)(14)(15) Antiviral therapy with interferonbased therapy has been demonstrated to improve patient survival and reduce the likelihood of liverrelated complications. (16)(17)(18) Historically, age has been a major limitation of antiviral treatment with interferon-based therapy because of its poor tolerability, adverse effects (AEs), and poorer response in older patients.…”

mentioning

confidence: 99%

Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older

et al. 2016

View full text Add to dashboard Cite

Elderly subjects have been historically underrepresented in clinical trials involving antiviral hepatitis C therapies. The aim of this analysis was to retrospectively evaluate the safety and efficacy of ledipasvir/sofosbuvir (LDV/SOF) by age groups of <65 years versus 65 years among subjects enrolled in phase 3 trials. Four open-label phase 3 clinical trials evaluated the safety and efficacy of LDV/SOF with or without ribavirin (RBV) for the treatment of genotype 1 chronic hepatitis C virus. Sustained virological response at 12 weeks, treatment-emergent adverse events (AEs), and graded laboratory abnormalities were analyzed according to age group. Of the 2293 subjects enrolled in four phase 3 trials, 264 (12%) were 65 years of age, of whom 24 were aged 75 years. Sustained virological response at 12 weeks was achieved by 97% (1965/ 2029) of subjects aged <65 years and 98% (258/264) of subjects aged 65 years. The most common AEs in both LDV/ SOF groups that occurred in 10% of subjects were headache and fatigue. The rate of study discontinuation due to AEs was similar in the two age cohorts. The use of RBV in 1042 (45%) subjects increased the number of AEs, treatmentrelated AEs, and AEs leading to study drug modification/interruption, particularly among elderly subjects. Conclusions: LDV/SOF with or without RBV was highly effective for treatment of genotype 1 chronic hepatitis C virusin subjects aged 65 and older. Addition of RBV did not increase sustained virological response at 12 weeks rates but led to higher rates of AEs, especially in elderly subjects. (HEPATOLOGY 2016;63:1112-1119 C hronic hepatitis C viral (HCV) infection is an important cause of morbidity and mortality in infected individuals worldwide.(1) The World Health Organization estimates that the worldwide prevalence of HCV infection is 2.2%, representing 123 million people.(2) Globally, HCV accounts for 27% of liver cirrhosis and 25% of hepatocellular carcinoma cases.(3) Although the rate of HCV is decreasing overall due to attrition from mortality, (4,5) the rate of HCV-related cirrhosis is anticipated to increase by Abbreviations: AE, adverse event; CI, confidence interval; eGFR, estimated glomerular filtration rate; HCV, hepatitis C virus; LDV/SOF, ledipasvir/sofosbuvir; RAV, resistance-associated variant; RBV, ribavirin; SVR12, sustained virological response at 12 weeks

show abstract

mentioning

confidence: 99%

Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Parenteral acquisition of HCV infection via contact with contaminated blood or blood products is now rare in many countries following the implementation of donor screening. However, children continue to be infected by unsterile medical injections, the receipt of unscreened blood, isolated hospital contamination outbreaks and their mothers (Prati 2006).…”

mentioning

confidence: 99%

Performance of diagnostic biomarkers in predicting liver fibrosis among hepatitis C virus-infected Egyptian children

Nassef

Shady

Galal

et al. 2013

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

“…9,10 The common risk factors (Table 2), which are usually related to HCV transmission, were not detected in any of the 9 HCV-infected subjects in this cohort. On the other hand, factors related to normal lifestyle of Bangladesh people may be related to HCV infection in these subjects (Table 2).…”

Section: Resultsmentioning

confidence: 67%

Prevalence and Risk Factors of Asymptomatic Hepatitis C Virus Infection in Bangladesh

Mamun-Al-Mahtab

Karim

Foster

et al. 2011

Journal of Clinical and Experimental Hepatology

View full text Add to dashboard Cite

Objectives: There are paucity of information about prevalence and risk factor of hepatitis C virus (HCV) in Bangladesh. Methods: Blood was collected from 1018 randomly selected subjects from a semi-urban area of Bangladesh. Anti-HCVs were checked in the blood twice using a third-generation commercial kit. The data of the questionnaires were analyzed to find possible risk factors. Results: Nine of the 1018 subjects (88%) were tested positive for anti-HCV. The HCV-positive subjects were >28 years old. Major risk factors for HCV infection were treatment by unqualified and traditional practitioners, history of massvaccination against smallpox, hair cutting and shaving by barbers, and body piercing. However, known risk factors such as blood transfusion, surgery, invasive therapy, and intravenous drug use were not detected in any HCV-infected subjects. Conclusion: Control of HCV infection in Bangladesh may be difficult because the risk factors are related to normal tradition and culture of Bangladeshi people.

show abstract

Transmission of hepatitis C virus by blood transfusions and other medical procedures: A global review

Cited by 220 publications

References 105 publications

Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older

Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older

Performance of diagnostic biomarkers in predicting liver fibrosis among hepatitis C virus-infected Egyptian children

Prevalence and Risk Factors of Asymptomatic Hepatitis C Virus Infection in Bangladesh

Contact Info

Product

Resources

About